Abstract 82MO
Background
Despite a long-known association between annual hospital volume and outcome, little progress has been made in shifting high-risk surgery from unsafe hospitals. This study investigates whether the risk-standardized mortality rate (RSMR) could serve as a stronger proxy for surgical quality than volume.
Methods
We included all patients who underwent complex oncologic surgeries in Germany between 2010 and 2018 for major lung cancer surgery, splitting the data into training (2010–2015) and validation sets (2016–2018). We calculated annual volume and RSMR quintiles in the training set and applied these thresholds to the validation set. We studied the overlap between the two systems, modelled a market exit of low-performing hospitals and compared effectiveness and efficiency of volume- and RSMR-based rankings. We compared travel distance/time that would be required to reallocate patients to the nearest hospital with low-mortality ranking for the specific procedure.
Results
Between 2016 and 2018, 28,647 patients were treated in 974 hospitals. 71.4% of all high-volume hospitals were not ranked in the low-mortality group according to RSMR grouping. In a RSMR centralization model, an average of 33 patients undergoing complex oncologic surgery would need to relocate to a low-mortality hospital to save one life, while 48 would need to relocate to a high-volume hospital. Mean difference in travel times between the nearest hospital to the hospital that performed surgery was 16 minutes. Centralization based on RSMR compared to volume would ensure lower median travel times, and these times would be lower than those observed.
Conclusions
RSMR is a promising proxy for measuring surgical quality. It outperforms volume in effectiveness, efficiency, and hospital availability for patients.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
131MO - Trends in age- and sex-specific lung cancer mortality in Europe and Northern America: analysis of vital registration data from the WHO Mortality Database between 2000 and 2017
Presenter: Philip Baum
Session: Mini Oral session 1
Resources:
Abstract
Slides
81MO - Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated Results
Presenter: Chao Lyu
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
108MO - Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
Presenter: Marina Garassino
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
109MO - Respect the Middle Lobe: Perioperative Survival of Bilobectomy Compared to Lobectomy and Pneumonectomy
Presenter: Andrew Li
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
157MO - Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy
Presenter: Marta Casarrubios
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
172MO - Analysis of comutations in DNA damage repair (DDR) related pathways with immunotherapeutic biomarkers in Chinese lung cancer patients
Presenter: Jun Li
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant of 131MO, 81MO and 108MO
Presenter: Leah Backhus
Session: Mini Oral session 1
Resources:
Slides
Webcast
Invited Discussant of 82MO and 109MO
Presenter: Alessandro Brunelli
Session: Mini Oral session 1
Resources:
Slides
Webcast
Invited Discussant of 157MO and 172MO
Presenter: Keith Kerr
Session: Mini Oral session 1
Resources:
Slides
Webcast
Q&A
Session: Mini Oral session 1
Resources:
Webcast